Next-generation dementia therapy’s Phase 3 clinical trials starts in Korea
The next generation dementia therapy, which was expected to generate approximately KRW 1 trillion prescriptions in the global market, was approved to conduct Phase 3 clinical trials in Korea.
The therapy is ‘RVT-101’ that is evaluated to follow the most popular one, ‘donepezil(product name: Aric...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
